PRD Therapeutics
Tokyo, JP · 4 known investors
PRD Therapeutics is a drug-discovery startup developing first-in-class oral SOAT2-selective inhibitors (PRD compounds derived from pyripyropene A) to regulate lipid metabolism. Its lead program targets the rare disease homozygous familial hypercholesterolemia (HoFH), with planned expansion to MASH/MASLD and other lipid-metabolism disorders.
Founders & leadership
細莞
細田 莞爾代表取締役社長 / President & Co-Founder
供洋
供田 洋社外取締役 / Co-Founder
Investors · 4
In the news
Frequently asked questions
- What does PRD Therapeutics do?
- PRD Therapeutics is a drug-discovery startup developing first-in-class oral SOAT2-selective inhibitors (PRD compounds derived from pyripyropene A) to regulate lipid metabolism. Its lead program targets the rare disease homozygous familial hypercholesterolemia (HoFH), with planned expansion to MASH/MASLD and other lipid-metabolism disorders.
- Who founded PRD Therapeutics?
- PRD Therapeutics was founded by 細田 莞爾, 供田 洋.
- Who are PRD Therapeutics's investors?
- PRD Therapeutics's investors include JIC Venture Growth Investments, JAFCO Group, Mizuho Capital, SMBC Venture Capital.
- Where is PRD Therapeutics headquartered?
- PRD Therapeutics is headquartered in Tokyo, JP.